Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • RESEARCH HIGHLIGHT

Long path to MYC inhibition approaches clinical trials

  1. M. Teresa Villanueva
    View author publications

    You can also search for this author in PubMed  Google Scholar

The transcription factor MYC is frequently deregulated and hyperactive in cancer, and many tumours depend on MYC to grow. However, despite being an obvious target, inhibiting MYC therapeutically has proved to be challenging. Now, a team led by Laura Soucek has shown that Omomyc, a MYC dominant-negative gene product that is used to inhibit MYC for research purposes, can penetrate cancer cells in vitro and in vivo, bringing it closer to evaluation in the clinic.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 18, 337 (2019)

doi: https://doi.org/10.1038/d41573-019-00055-2

References

  1. Beaulieu, M.-E. et al. Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy. Sci. Transl Med. 11, eaar5012 (2019)

    Article  PubMed  Google Scholar 

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links